New pancreatic cancer drug hailed as ‘closest thing to a cure’

A new once-daily pill for advanced pancreatic cancer cleared the disease in one in 12 patients when combined with chemotherapy, a clinical trial suggests.

The study, presented at the European Organization for Research and Treatment of Cancer in Barcelona, ​​found that combining daraxonrasib with chemotherapy increased the proportion of patients alive after one year compared to standard treatment.

The trial’s lead doctor said the results represented the “closest thing” to a “cure” for some patients.

Daraxonrasib made headlines in May after it was found to nearly double the survival time of patients with aggressive and advanced pancreatic cancer compared to chemotherapy alone. It also caused fewer side effects.

The drug works by locking onto the mutated KRAS gene, found in more than nine out of 10 pancreatic tumors, and continuously signals cancer cell growth.

By disabling this function, the drug can prevent tumors from spreading.

CT scan before and after treatment with Daraxonrasib plus chemotherapy (gemcitabine and nabpaclitaxel)
CT scan before and after treatment with Daraxonrasib plus chemotherapy (gemcitabine and nabpaclitaxel) ( Pennsylvania )

In the new study, tumors shrank or disappeared in 60.7 percent of patients who received daraxonrasib and chemotherapy.

This included complete responses in 8.2 percent of patients over a typical 18-month follow-up, meaning their tumors were no longer detectable.

Overall, tumors stopped growing in 90.2 percent of the 61 patients studied (the disease control rate) over a typical 18-month period.

One year after treatment, 76.6 percent of patients were still alive. This compares to about 40 to 45 percent of patients when they receive chemotherapy alone.

It also took 12.8 months on average for tumors to recur or start growing again when the entire patient group is considered, the phase one/two clinical trial showed.

Dr. Wungki Park, an oncologist at Memorial Sloan Kettering Cancer Center in New York, who presented the results, said he had never seen such responses, adding that it represented “a massive, massive advance” in the treatment of pancreatic cancer.

“In about one in 12 patients, the cancer completely disappeared,” he said.

“And then, with such a long follow-up, it’s real. We’ve never seen anything like this.”

The trial's lead doctor said the results represented the
The trial’s lead doctor said the results represented the “closest thing” to a “cure” for some patients. ( Pennsylvania )

When asked if one in 12 patients whose tumors were not visible were considered cured, he replied: “That’s the closest we’ll get to a cure.”

“We’re almost at the discovery level; we’ve never seen an eight percent complete response in metastatic pancreatic cancer, you don’t see that….

“The median follow-up is 18 months. Imagine, in 18 months on average, your disease disappears on the scan… it’s the closest you can get to remission… it’s incredible.”

He said longer-term survival data would come as the trial progressed, but there is “some survival signal here, which is very strong”, with 76.6 percent of patients alive after one year.

Less than five percent of patients in the trial stopped treatment, which is considered low.

Dr. Park said cancer frequently develops resistance to drug treatments, but “we’re delaying that as much as possible” with the new combination treatment.

The final phase three study in the United States has enough patients, but some sites in Europe may have enough room.

Main symptoms of pancreatic cancer

NHS


Symptoms of pancreatic cancer may include:

  • the whites of your eyes or skin turn yellow (jaundice), and you may also have itchy skin, darker pee, and paler poop than usual
  • loss of appetite or weight loss without trying to
  • feeling tired or lacking energy
  • a high temperature or feeling hot, cold, or chilly

Other symptoms can affect your digestion, such as:

  • feel or be sick
  • diarrhea or constipation, or other changes in your stools
  • pain in the upper stomach and back, which may get worse when you eat or lie down and get better when you bend forward
  • symptoms of indigestion, such as feeling bloated

Dr Madina Kara, head of research at Pancreatic Cancer UK, said: “Half of people with pancreatic cancer die within three months of diagnosis and their loved ones would give anything to spend more precious time with them.

“This is a small initial study, but these encouraging results now show that daraxonrasib and chemotherapy can be effective when used in combination. »

She said the team was excited about the larger clinical trial, adding: “These results are part of a growing body of evidence that offers real hope for people with advanced pancreatic cancer. »

She said: “The UK Government must ensure that we build on the momentum we are seeing by increasing investment in pancreas research and clinical trials, so that more patients can take part in studies that can improve outcomes.

“It must also ensure that there is a rapid pathway to deliver ground-breaking new treatments to patients across the UK as soon as they are proven to work.”

More than 11,000 people are diagnosed with pancreatic cancer each year in the UK and more than 10,000 die from it, usually within a few months.

Michelle Mitchell, chief executive of Cancer Research UK, said: “This is the biggest step forward we have seen in decades for pancreatic cancer patients and could offer real hope to people facing one of the deadliest and most difficult to treat cancers.

“Further trials are now needed before this treatment can be evaluated for use on the NHS and despite this progress, survival from pancreatic cancer is still very low.

“More research is needed to determine how this drug could be used in conjunction with other therapies to give patients the best chance of beating the disease. »

Gn headline

Logo